We are live on ! Find out more
ABUS icon

Arbutus Biopharma

48 hedge funds and large institutions have $100M invested in Arbutus Biopharma in 2014 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 6 increasing their positions, 18 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 12

23% more funds holding

Funds holding: 3948 (+9)

3% more capital invested

Capital invested by funds: $97.6M → $100M (+$2.77M)

39% less call options, than puts

Call options by funds: $11.6M | Put options by funds: $19.1M

67% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 18

Holders
48
Holders Change
+9
Holders Change %
+23.08%
% of All Funds
1.39%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
21
Increased
6
Reduced
18
Closed
12
Calls
$11.6M
Puts
$19.1M
Net Calls
-$7.5M
Net Calls Change
-$7.92M
Name Holding Trade Value Shares
Change
Change in
Stake
Franklin Resources
1
Franklin Resources
California
$22.1M -$20M -1,225,600 -54%
Bank of Montreal
2
Bank of Montreal
Ontario, Canada
$17.4M -$53.5K -3,276 -0.4%
BBA
3
Baker Bros. Advisors
New York
$10.2M
Morgan Stanley
4
Morgan Stanley
New York
$9.36M +$6.82M +417,570 +1,647%
BA
5
BlackRock Advisors
Delaware
$7.93M -$668K -40,900 -10%
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
$4.56M +$3.52M +215,861 New
Canada Pension Plan Investment Board
7
Canada Pension Plan Investment Board
Ontario, Canada
$3.75M +$2.89M +176,700 New
AWMDMG
8
Austin W. Marxe & David M. Greenhouse
New York
$3.7M -$4.83M -295,595 -63%
BG
9
BlackRock Group
United Kingdom
$2.41M
Tudor Investment Corp
10
Tudor Investment Corp
Connecticut
$2.11M +$1.63M +100,000 New
U
11
UBS
Switzerland
$2.08M +$1.58M +96,998 +6,467%
OSAM
12
O'Shaughnessy Asset Management
Connecticut
$1.88M -$14.6K -893 -1%
HSBC Holdings
13
HSBC Holdings
United Kingdom
$1.53M -$1.18M -72,000 -50%
ARTA
14
A.R.T. Advisors
New York
$1.41M +$1.09M +66,583 New
Jane Street
15
Jane Street
New York
$1.15M +$885K +54,179 New
BlackRock
16
BlackRock
New York
$1.14M -$71.8K -4,400 -8%
EGM
17
Espalier Global Management
New York
$1.06M +$816K +50,000 New
Deutsche Bank
18
Deutsche Bank
Germany
$974K -$117K -7,146 -13%
VKH
19
Virtu KCG Holdings
New York
$942K +$317K +19,416 +77%
BIM
20
BlackRock Investment Management
Delaware
$507K
Nomura Holdings
21
Nomura Holdings
Japan
$501K -$570K -34,932 -59%
Renaissance Technologies
22
Renaissance Technologies
New York
$485K -$2.08M -127,300 -85%
Royal Bank of Canada
23
Royal Bank of Canada
Ontario, Canada
$340K -$286K -17,540 -52%
LP
24
LMR Partners
United Kingdom
$337K +$260K +15,895 New
CA
25
Commerzbank Aktiengesellschaft
Germany
$298K +$230K +14,100 New

ABUS Hedge Fund Activity: Q3 2014 in Review

48 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2014, worth a combined $100M — up 2.8% from $97.6M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new ABUS positions and 12 closed out — a net gain of 9 holders — while 6 added to existing stakes and 18 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $6.82M. The largest seller was Franklin Resources, cutting an estimated $20M.

  • 48 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2014, up from 39 in Q2 2014.
  • Funds reported $100M of Arbutus Biopharma stock for Q3 2014, up 2.8% quarter-over-quarter.
  • 21 funds opened new Arbutus Biopharma positions in Q3 2014 and 12 closed out, a net change of +9 holders.
  • The largest Arbutus Biopharma buyer in Q3 2014 was Morgan Stanley, an estimated $6.82M added.
  • The largest Arbutus Biopharma seller in Q3 2014 was Franklin Resources, an estimated $20M sold.

Based on aggregated 13F filings for Q3 2014.